Drug intelligence / Profile preview

colchicine + dapsone

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of colchicine and dapsone used primarily for treating complex aphthosis and colchicine-resistant Familial Mediterranean Fever (FMF). This combination has shown significant effectiveness in patients who don't respond adequately to colchicine alone. The medications work through different but complementary anti-inflammatory mechanisms, with colchicine typically used as first-line therapy and dapsone added for enhanced efficacy.

Targets

TUBB (Tubulin (alpha and beta subunits))MPO (Myeloperoxidase)DHPS (Dihydropteroate synthase)

Beyond the preview

Go deeper on colchicine + dapsone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on colchicine + dapsone.

Explore the full profile